Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US

Lund, October 24, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod as treatment of eye diseases associated with excessive vascularization. The patent will be issued on 25 October, 2022, under patent number 11,478,465 and provides protection and market exclusivity in this field of use until 2040.

The patent covers the medical use of des-ethyl laquinimod for treatment of sight-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy. Active Biotech already has an issued patent, for the use of laquinimod in eye diseases associated with excessive vascularization, in Europe.

“The now granted US patent is a result of our diligent work with our patent portfolio of laquinimod aiming to optimize the protection of its use in devastating eye disorders with high medical need”, said Helén Tuvesson, CEO.